GENMAB A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,030 DKK | +1.20% |
|
-1.36% | -5.80% |
| Apr. 16 | Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug | MT |
| Apr. 16 | Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024 | CI |
ETFs positioned on Genmab A/S
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.64% | 192 M€ | +11.68% | ||
| 1.28% | 49 M€ | +4.80% | ||
| 1.01% | 96 M€ | -4.54% | ||
| 0.75% | 18 M€ | +2.56% | - | |
| 0.56% | 717 M€ | +4.69% | ||
| 0.49% | 88 M€ | +10.37% | - | |
| 0.45% | 26 M€ | +0.81% | - | |
| 0.33% | 6 M€ | -.--% | - | |
| 0.33% | 4 M€ | -.--% | - | |
| 0.32% | 36 M€ | +0.59% | - | |
| 0.31% | 6 M€ | -.--% | ||
| 0.29% | 2 M€ | +9.19% | - | |
| 0.29% | 2 M€ | -.--% | - | |
| 0.24% | 29 M€ | +8.37% | - | |
| 0.20% | 7 M€ | +1.02% | - | |
| 0.19% | 21 M€ | +0.63% | - | |
| 0.14% | 3,859 M€ | +18.82% | - | |
| 0.14% | 469 M€ | -2.05% | - | |
| 0.14% | 10 M€ | -3.35% | - | |
| 0.09% | 276 M€ | +11.40% | - | |
| 0.08% | 277 M€ | -.--% | - | |
| 0.08% | 194 M€ | +4.90% | - | |
| 0.08% | 441 M€ | +8.15% | ||
| 0.07% | 7 M€ | +0.11% | - | |
| 0.06% | 0 M€ | 0.00% | - | |
| 0.04% | 273 M€ | +13.05% | ||
| 0.04% | 206 M€ | -.--% | ||
| 0.04% | 1,166 M€ | +0.26% | - | |
| 0.04% | 607 M€ | +0.05% | - | |
| 0.04% | 23 M€ | -.--% | - | |
| 0.04% | 786 M€ | -.--% |
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
2,030
DKK
Average target price
2,434
DKK
Spread / Average Target
+19.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.80% | 18.79B | |
| +2.49% | 96.73B | |
| -1.86% | 21.31B | |
| -16.61% | 21.21B | |
| -42.14% | 16.37B | |
| -27.40% | 13.68B | |
| +1.44% | 13.44B | |
| +21.29% | 10.98B | |
| -21.79% | 8.56B | |
| +12.82% | 8.12B |
- Stock Market
- Equities
- GMAB Stock
- Funds and ETFs Genmab A/S
